成功取栓后辅助动脉内阿替普酶治疗急性缺血性卒中:CHOICE-2随机临床试验
CHOICE-2多中心随机开放标签试验纳入440例大血管闭塞且取栓成功(eTICI 2b50-3)的急性缺血性卒中患者,比较辅助动脉内阿替普酶(0.225 mg/kg,最大20 mg)与单纯取栓。
要点
- 取栓成功后辅助动脉内阿替普酶可提高90天良好功能预后比例。
- 辅助治疗未显著增加症状性颅内出血风险。
- 辅助治疗组90天死亡率较高,需进一步研究验证。
核心结论
- 成功取栓后辅助动脉内阿替普酶可提高90天极佳功能预后比例,且未显著增加症状性颅内出血。
- 辅助治疗组90天死亡率较高,需进一步研究。
研究设计与样本
- 随机、开放标签、盲法结局评估试验,在西班牙14个卒中中心开展,2023年12月11日至2025年11月26日。
- 共440例大血管闭塞急性缺血性卒中患者随机,取栓后eTICI 2b50-3,随机分为辅助动脉内阿替普酶组(n=221)或单纯取栓组(n=219)。
- 433例按随机方案治疗,中位年龄76岁(IQR 75-78),女性51%。
主要发现
- 6个次要结局中4个无显著组间差异。
关键数值与推荐
- 辅助动脉内阿替普酶剂量0.225 mg/kg,最大20 mg,15分钟内输注。
- 主要结局为90天mRS 0-1;残余低灌注通过随访CT灌注评估。
临床怎么用
- 对于大血管闭塞取栓成功(eTICI 2b50-3)的患者,可考虑辅助动脉内阿替普酶以改善功能预后。
- 需权衡死亡率升高信号,个体化决策并密切监测。
局限性
- 开放标签设计,尽管结局评估盲法。
- 死亡率差异需进一步研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Despite high recanalization rates with endovascular thrombectomy for acute ischemic stroke due to large vessel occlusion, functional outcomes remain suboptimal. The benefit of adjunctive intra-arterial thrombolysis after successful thrombectomy is uncertain. OBJECTIVE: To assess whether adjunctive intra-arterial alteplase after successful thrombectomy improves functional outcomes and cerebral reperfusion. DESIGN, SETTING, AND PARTICIPANTS: Randomized, open-label trial with blinded outcome assessment conducted at 14 stroke centers in Spain from December 11, 2023, through November 26, 2025. A total of 440 patients with acute ischemic stroke due to large vessel occlusion treated with thrombectomy within 24 hours and achieving an expanded Treatment in Cerebral Ischemia score of 2b50 to 3 were randomized. INTERVENTIONS: Thrombectomy plus intra-arterial alteplase (0.225 mg/kg; maximum dose, 20 mg) infused over 15 minutes (n = 221) or thrombectomy alone (n = 219). MAIN OUTCOMES AND MEASURES: The primary outcome was an excellent functional outcome at 90 days, which was defined as a modified Rankin Scale score of 0 or 1. There were 6 secondary outcomes, including residual hypoperfusion on follow-up computed tomography perfusion. The safety outcomes included symptomatic intracranial hemorrhage and death. RESULTS: Of 3786 patients treated with thrombectomy, 2776 (73%) fulfilled angiographic criteria and 440 (12%) were randomized. There were 433 patients who were treated as randomized (median age, 76 [IQR, 75-78] years; 51% female). At 90 days, 57.5% of patients (123/214) in the thrombectomy plus intra-arterial alteplase group had a modified Rankin Scale score of 0 or 1 vs 42.5% of patients (93/219) in the thrombectomy alone group (adjusted risk difference, 15.0% [95% CI, 5.7% to 24.3%]; P = .002). Of 6 secondary outcomes, 4 showed no significant between-group differences. Residual hypoperfusion occurred in 28.6% (55/192) of patients in the thrombectomy plus intra-arterial alteplase group vs 50.5% (96/190) of patients in the thrombectomy alone group (adjusted risk difference, -22.0% [95% CI, -31.5% to -12.4%]; P < .001) and symptomatic intracranial hemorrhage occurred in 1.4% (3/214) vs 0.5% (1/219), respectively (adjusted odds ratio, 3.10 [95% CI, 0.32 to 30.0]; P = .33). Mortality at 90 days was 12.1% (26/214) in the thrombectomy plus intra-arterial alteplase group vs 6.4% (14/219) in the thrombectomy alone group (adjusted risk difference, 5.9% [95% CI, 0.5% to 11.3%]; P = .03). CONCLUSIONS AND RELEVANCE: Among patients with acute ischemic stroke and successful thrombectomy, adjunctive intra-arterial alteplase increased the proportion achieving excellent functional outcome at 90 days without a significant increase in symptomatic intracranial hemorrhage. Higher mortality in the thrombectomy plus intra-arterial alteplase group warrants further study. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05797792.
引用
- Renú A, Fernández-Couto MD, de la Riva P, et al. Adjunctive Intra-Arterial Alteplase After Successful Thrombectomy for Acute Ischemic Stroke: The CHOICE-2 Randomized Clinical Trial. JAMA. 2026. PMID: 42096239. doi:10.1001/jama.2026.5164
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。